Additional warnings for Chantix
The labeling for Chantix (varenicline tartrate, from Pfizer) has been updated with a warning to observe patients for serious neuropsychiatric symptoms, including changes in behavior, agitation, depressed mood, suicidal ideation and suicidal behavior. These symptoms, as well as a worsening of pre-existing psychiatric illness, may be complicated by the symptoms of nicotine withdrawal in patients who stopped smoking. Additionally, some patients who continued to smoke also reported experiencing nicotine withdrawal symptoms. Chantix is a non-nicotine prescription treatment indicated for smoking cessation in adults.
For more information call (800) 438-1985 or visit www.chantix.com.